不可手术NSCLC常规剂量放化疗后症状性心脏事件的剂量学预测因素
该研究回顾性分析了140例2007至2015年接受同步放化疗的不可手术NSCLC患者,中位放疗剂量61.2 Gy。中位随访47.4个月,40例(28.6%)发生47次症状性心脏事件,中位至首次事件时间15.3个月。多因素分析显示全心脏剂量和基线心脏状态与症状性心脏事件风险增加相关,全心脏平均剂量≥20 Gy者4年累积发生率48.6%对比<20 Gy者18.5%(p=0.0002),症状性心脏事件与死亡独立相关(p=0.0001)。
要点
- 全心脏平均剂量≥20 Gy者4年症状性心脏事件累积发生率显著高于<20 Gy者(48.6% vs 18.5%,p=0.0002)。
- 全心脏、心室和左前降支剂量与急性冠脉综合征/充血性心力衰竭相关。
- 症状性心脏事件与死亡独立相关(p=0.0001),支持最小化心脏剂量。
核心结论
- 不可手术NSCLC患者接受常规剂量放化疗时,心脏意外照射与后续症状性心脏事件相关,尤其是急性冠脉综合征和充血性心力衰竭。
- 症状性心脏事件与较差生存独立相关,支持在常规剂量放化疗中最小化心脏剂量。
研究设计与样本
- 回顾性队列研究,纳入2007至2015年接受同步放化疗的140例不可手术NSCLC患者。
- 中位随访47.4个月,中位放疗剂量61.2 Gy(四分位距60至66 Gy)。
- 采用竞争风险分析估计至心脏事件时间。
主要发现
- 40例(28.6%)发生47次症状性心脏事件,中位至首次事件时间15.3个月。
- 多因素分析显示较高全心脏剂量和基线心脏状态与症状性心脏事件风险增加相关。
- 全心脏平均剂量≥20 Gy者4年累积发生率为48.6%,<20 Gy者为18.5%(p=0.0002)。
- 全心脏、心室和左前降支剂量与急性冠脉综合征/充血性心力衰竭相关;全心脏和心房剂量与室上性心律失常无关。
- 症状性心脏事件与死亡独立相关(p=0.0001)。
临床怎么用
- 对不可手术NSCLC接受常规剂量放化疗者,应关注全心脏及心脏亚结构剂量,尽量最小化心脏照射。
- 全心脏平均剂量≥20 Gy者症状性心脏事件风险显著升高,提示需加强心脏监测与随访。
局限性
- 回顾性研究设计,样本量140例,可能存在选择偏倚和未测量混杂。
- 单中心数据,结果外推需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: We hypothesized that higher cardiac doses correlates with clinically significant cardiotoxicity after standard-dose chemoradiation therapy (CRT) (∼60 Gy) for inoperable NSCLC. METHODS: We retrospectively reviewed the records of 140 patients with inoperable NSCLC treated with concurrent CRT from 2007 to 2015. Extracted data included baseline cardiac status, dosimetric parameters to the whole heart (WH) and cardiac substructures, and the development of post-CRT symptomatic cardiac events (acute coronary syndrome [ACS], arrhythmia, pericardial effusion, pericarditis, and congestive heart failure [CHF]). Competing risks analysis was used to estimate time to cardiac events. RESULTS: Median follow-up was 47.4 months. Median radiation therapy dose was 61.2 Gy (interquartile range, 60 to 66 Gy). Forty patients (28.6%) developed 47 symptomatic cardiac events at a median of 15.3 months to first event. On multivariate analysis, higher WH doses and baseline cardiac status were associated with an increased risk of symptomatic cardiac events. The 4-year cumulative incidence of symptomatic cardiac events was 48.6% versus 18.5% for mean WH dose ≥ 20 Gy versus < 20 Gy, respectively (p = 0.0002). Doses to the WH, ventricles, and left anterior descending artery were associated with ACS/CHF, whereas doses to the WH and atria were not associated with supraventricular arrhythmias. Symptomatic cardiac events (p = 0.0001) were independently associated with death. CONCLUSIONS: Incidental cardiac irradiation was associated with subsequent symptomatic cardiac events, particularly ACS/CHF, and symptomatic cardiac events were associated with inferior survival. These results support the minimization of cardiac doses among patients with inoperable NSCLC receiving standard-dose CRT.
引用
- Yegya-Raman N, Wang K, Kim S, et al. Dosimetric Predictors of Symptomatic Cardiac Events After Conventional-Dose Chemoradiation Therapy for Inoperable NSCLC. J Thorac Oncol. 2018. PMID: 29883836. doi:10.1016/j.jtho.2018.05.028
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。